UTI Antibiotic Options Beyond Trimethoprim-Sulfamethoxazole

TMP-SMX, the generic antibiotic sold under names like Bactrim, still works as a first-line UTI treatment in plenty of places. Among US E. coli isolates tested in 2022, TMP-SMX susceptibility sat well below the rates seen for nitrofurantoin and fosfomycin. That gap tells a clear story: TMP-SMX has lost ground, and the two alternatives have held theirs.

IDSA guidelines set a specific line here: clinicians should not prescribe TMP-SMX empirically (meaning before culture results come back) once local E. coli resistance passes 20%. A clinician who prescribes it anyway without culture data is accepting real odds of failure before the patient even knows whether the drug is working.

Resistance is only one piece of this. Several patient groups cannot use TMP-SMX regardless of local resistance rates. Pregnancy complicates things further: TMP-SMX is contraindicated in the first trimester because of folate antagonism risk, and again near term because of kernicterus risk in the newborn. And a patient whose prior culture already showed resistance has no business getting the same prescription again.

These groups add up to a sizable share of people walking into a clinic with UTI symptoms who simply are not candidates for TMP-SMX as a first try. That makes the alternatives, not TMP-SMX, the everyday reality for a large slice of UTI care.

Nitrofurantoin and fosfomycin as the established first-line replacements

For most people with an uncomplicated bladder infection who can't take TMP-SMX, nitrofurantoin or fosfomycin gets the job done. Both work about as well, both have solid safety records, and neither forces a jump straight to a broader-spectrum drug.

Nitrofurantoin, sold as Macrobid or Macrodantin, showed dramatically higher susceptibility than TMP-SMX among 2022 US E. coli isolates. The drug concentrates in urine, where it disrupts bacterial DNA through a multi-step reduction process inside the bacterial cell. Typical dosing is 100 mg of the monohydrate/macrocrystal form (Macrobid) twice daily for 5 to 7 days, and some evidence supports a shorter 5-day course for uncomplicated cystitis.

Nitrofurantoin isn't for everyone. Patients with significant kidney impairment, specifically a creatinine clearance under 30 mL/min, don't get enough drug concentration for the mechanism to work. Compared with TMP-SMX, though, it carries fewer drug interactions and works fine for patients with sulfa allergies.

Fosfomycin, sold as Monurol, offers something nitrofurantoin doesn't: a single 3-gram packet, dissolved in water, taken once. If a patient struggles to finish a multi-day course, this is a real adherence advantage. IDSA lists it as an acceptable first-line alternative. Its clinical cure rate runs slightly below a full nitrofurantoin course, generally landing in the high 50s to low 70s percent, depending on the regimen you use. Fosfomycin's coverage is narrower, too: it works mainly against E. coli and Enterococcus faecalis, so it isn't the right choice when the infecting organism is unknown or atypical. It also costs more out of pocket than nitrofurantoin, which matters for uninsured patients weighing options.

What both drugs share matters as much as how they differ.

When fluoroquinolones become necessary despite being second-line

Fluoroquinolones like ciprofloxacin kill UTI-causing bacteria effectively. The reason they aren't the next thing to reach for once nitrofurantoin or fosfomycin isn't on the table has nothing to do with whether they work and everything to do with their safety profile.

The FDA has attached boxed warnings, the strongest warning category the agency uses, to fluoroquinolones covering tendon rupture, peripheral neuropathy, central nervous system effects, worsening of myasthenia gravis, and aortic aneurysm and dissection. QT prolongation appears separately, listed under Warnings and Precautions. These risks are serious enough that the ciprofloxacin label itself reserves the drug for uncomplicated cystitis only when no other treatment option exists.

Resistance adds another layer to the caution. If a patient has taken a fluoroquinolone within roughly the past three months, a new infection faces meaningfully higher odds of resisting the same class. The 2025 IDSA guidelines specifically advise against empiric fluoroquinolone use in patients with recent exposure, and the shorter that interval, the higher the flagged resistance risk.

None of this makes fluoroquinolones a lesser drug. Complicated UTI, including pyelonephritis, is one such case, particularly when culture results or a severe allergy rule out other agents. Prostatitis is another: fluoroquinolones penetrate prostate tissue in a way that nitrofurantoin and fosfomycin simply do not. When culture results confirm resistance to every first-line option, a fluoroquinolone becomes the logical next step.

If a first prescription for a simple bladder infection turns out to be ciprofloxacin, it's reasonable to ask the clinician what led there. What contraindication ruled them out? Asking what contraindication ruled out other options is the kind of informed question this whole landscape is built to support.

Oral beta-lactams: when they enter the picture

Oral beta-lactams, including cephalexin and amoxicillin/clavulanate, don't outperform the first-line options for a standard uncomplicated UTI. They earn their place by being available to patients who can't use anything else, and recent evidence has expanded where that place includes.

For uncomplicated infections, head-to-head data show the tradeoffs clearly. Cephalexin (Keflex) has worse efficacy and higher relapse rates than nitrofurantoin or TMP-SMX in direct comparisons. It's the drug that works when nitrofurantoin or TMP-SMX can't be used. Typical dosing runs 250 to 500 mg, four times daily, for 3 to 7 days. Its clearest niche is pregnancy: cephalexin is commonly prescribed in the first and second trimesters and is considered one of the safer options available during that window, alongside fosfomycin.

Complicated UTI is where the evidence has moved recently. A 2026 systematic review published in Pharmacotherapy found that select oral beta-lactams performed comparably to fluoroquinolones or TMP-SMX for complicated UTIs in appropriately selected patients. Rising resistance to first-line agents, paired with growing caution around fluoroquinolone toxicity, is what's driving that shift. Beta-lactams work by disrupting bacterial cell-wall synthesis, so their mechanism differs from every other class discussed here. That distinction matters most for a patient who has already run out of options because of resistance or allergy.

In men, the picture gets more specific. A 2026 VA retrospective cohort study comparing oral antibiotics in male outpatients with uncomplicated UTI found that beta-lactams carried a modestly higher rate of UTI-related return visits compared with fluoroquinolones, though hospitalization rates didn't differ. That finding supports caution around beta-lactams in men, particularly when TMP-SMX or a fluoroquinolone is available and appropriate instead. It's a nuance that matters more now that updated IDSA guidelines define uncomplicated UTI in men, as in women, as infection confined to the bladder.

Two newly approved agents that expand the toolkit for resistant and complicated infections

Two recent FDA approvals give patients options when the established toolkit runs out: gepotidacin, approved in March 2025 under the brand name Blujepa, and tebipenem pivoxil, approved in June 2026 under the brand name Utebzi.

Gepotidacin represents the first new antibiotic class for UTI treatment in nearly 30 years. The FDA approved it in March 2025 for uncomplicated UTIs in female adults and adolescents aged 12 and older. Tested against the same 2022 collection of US E. coli isolates used throughout this piece, gepotidacin inhibited a large majority of strains at the relevant concentration threshold, outperforming both ciprofloxacin and TMP-SMX from that same sample. A genuinely new mechanism of action means most patients carry no pre-existing cross-resistance from prior antibiotic use, so a drug-resistant infection isn't automatically resistant to this one too.

Pivmecillinam, sold as Pivya, got FDA approval in April 2024, and women with infections resistant to first-line agents can use it.

Tebipenem pivoxil stands apart as the first oral carbapenem approved for use in adult patients. The FDA approved it on June 17, 2026, for complicated urinary tract infections, including pyelonephritis, in adult patients with limited or no alternative oral treatment options. Carbapenems have historically meant IV administration and hospital admission. An oral version changes that equation: appropriate patients with complicated UTI may now avoid the hospital stay that this drug class used to require. Tebipenem met its pre-specified non-inferiority margin at the test-of-cure visit, about 17 days after the first dose. Broad availability to US patients is expected by the end of 2026, so it isn't yet something most patients can walk in and ask for.

These approvals don't argue for skipping the proven first-line drugs that work for most people. They're reassurance that even infections resistant to the current standard of care now have somewhere to go.

How antibiotic selection changes in specific patient groups

The same burning sensation and urgency can call for different antibiotics depending on who's experiencing them. Recognizing which category applies is the first useful thing a patient can bring into a conversation with a clinician.

Pregnancy narrows the list considerably. Cephalexin, fosfomycin, and nitrofurantoin are the preferred options in the first and second trimesters. Nitrofurantoin should be avoided after 36 weeks because of neonatal hemolytic anemia risk, and TMP-SMX should be avoided both in the first trimester, due to folate antagonism, and near term, due to kernicterus risk. Pregnant patients should always be evaluated by a clinician rather than relying on a self-selected or telehealth-only pathway.

UTI in men has historically been treated as automatically complicated. Updated IDSA guidelines now define uncomplicated UTI in men, the same as in women, as infection limited to the bladder, which allows shorter courses of select oral antibiotics instead of defaulting to extended, IV-equivalent regimens. The 2026 VA study found TMP-SMX performed comparably to fluoroquinolones on return visit rates in male outpatients, while nitrofurantoin and beta-lactams carried a modestly higher risk, which makes TMP-SMX and fluoroquinolones the preferred choices in men when they're appropriate. When prostatitis is suspected specifically, antibiotic choice shifts toward drugs that penetrate prostate tissue, mainly fluoroquinolones or TMP-SMX, since nitrofurantoin and fosfomycin don't reach adequate concentrations there.

Pyelonephritis, a kidney infection, changes the calculus. Fever above 100.4°F, flank or back pain, or other systemic symptoms point to kidney involvement. Fluoroquinolones, or in severe cases IV agents, become the relevant options, and now that it's approved, oral tebipenem pivoxil can follow. Pyelonephritis calls for in-person evaluation. Telehealth isn't the right starting point when these symptoms show up.

Different situations call for different drugs. What stays constant is the patient's job: know your own history and context well enough to describe it accurately.

Determining a UTI before seeing a clinician

A patient who understands their own symptom profile, antibiotic history, and red-flag signs can make a UTI consultation genuinely more productive. That same information still needs a clinician to translate it into a safe prescribing decision.

Some things are well within a patient's ability to observe and describe. Classic bladder infection symptoms include burning during urination (dysuria), increased frequency, pain above the pubic bone, cloudy urine, and a strong odor. Fever above 100.4°F or flank and back pain are red flags that point toward kidney involvement and call for in-person evaluation rather than telehealth. Knowing when symptoms started, and whether they've gotten worse, stayed the same, or partly improved, adds useful detail too.

A short history, brought to any UTI consultation, sharpens the whole exchange. How many UTIs has the patient had in the past year? This is probably the most actionable thing a patient can offer, because recent antibiotic use drives resistance risk assessment directly. Known kidney function issues round out the list.

Some questions sit outside what a patient can reasonably answer alone. Whether an infection is bacterial or viral isn't something to guess at: bacterial UTIs need antibiotics, viral illnesses don't, and treating the wrong one with antibiotics just adds to the resistance problem described at the start of this piece. Local resistance rates drive empiric prescribing decisions, but a patient can't access or interpret them without clinical support. If symptoms point to a bladder infection or something that's reached the kidneys, that changes which antibiotics are appropriate and whether in-person care is needed. And whether a given antibiotic is safe given a patient's full medication list and medical history is a judgment call that belongs to the clinician holding that full picture.

Telehealth and AI-assisted triage in UTI care, and their limits

For most straightforward UTIs, telehealth paired with AI-assisted triage is a legitimate first step, and a far cheaper one than a trip to urgent care or the emergency room, as long as the workflow includes real human oversight and clear rules for when to escalate.

Telehealth does several things well here. Many platforms can also order a lab culture at a nearby location when symptoms look atypical, keep recurring despite treatment, or when confirming the diagnosis before prescribing makes clinical sense.

Human oversight stays non-negotiable in several places. AI handles triage; licensed clinicians make the prescribing decision. A January 2026 clinical guide specifies that clinicians need to be deliberate about who can safely receive empiric antibiotics, that urine testing should be prioritized for higher-risk patients and for all men, and that telehealth workflows need clear paths to in-person care whenever symptoms suggest complications or real diagnostic uncertainty. Pregnant patients, anyone with fever or flank pain, and anyone whose symptoms haven't cleared after 48 to 72 hours of treatment all need to be seen in person.

If you walk into a telehealth visit prepared, the whole process works better. And stay ready to escalate to in-person care if that's what the clinician recommends. Telehealth is the right first step for the overwhelming majority of everyday UTI cases. It was never meant to replace every clinical situation that walks through the door.

Knowing which antibiotics exist and why each one fits a particular situation doesn't replace a clinician's judgment. It sharpens the conversation a patient gets to have with the person who will actually exercise that judgment.